Expansion Stage to Compare Opamtistomig Plus Chemotherapy Head-to-Head With Tislelizumab Plus Chemotherapy in Previously Untreated Disease NANJING, China, Oct. 20, 2026 (GLOBE NEWSWIRE) — Nanjing Leads Biolabs Co., Ltd. (“Leads...
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Stage in Phase II First-Line Gastric Cancer Study
